BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced 510(k) clearance ...

BD (NYSE: BDX) announced today that it received FDA 510(k) clearance for its Phasix ST umbilical hernia patch.

"BD treats first subject in trial of bioabsorbable scaffold" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been ...

The global bioabsorbable stents market size was US$ 221.5 million in 2021. The global bioabsorbable stents market is forecast to grow to US$ 351.5 million by 2030 by growing at a compound annual ...

The coronary stent market in the Asia-Pacific (APAC) region is witnessing sustained growth, driven by rising coronary artery ...

FRANKLIN LAKES, N.J., March 20, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the first patient treated in an ...

BD’s pivotal STANCE study evaluates whether the bioabsorbable GalaFLEX LITE Scaffold can reduce CC recurrence and implant malposition compared with standard revision surgery without a supportive ...

In the PROGRESS-AMS trial, Erbel and colleagues assessed the feasibility of bioabsorbable coronary stents made from a magnesium alloy—demonstrated in animal pilot studies to be completely ...

China plays a central role in this regional trend, as the country has seen a substantial rise in percutaneous coronary ...

You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...